Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shaman Pharmaceuticals Inc.

www.shamanbotanicals.com

Latest From Shaman Pharmaceuticals Inc.

Fulyzaq Review Shows FDA Adapting Smoothly To Adaptive Trial Design

Review documents show that Fulyzaq’s clear, if modest, treatment effect compared to placebo was buttressed by a series of exploratory subgroup analyses suggesting greater efficacy in sicker patients.

BioPharmaceutical Clinical Trials

Salix Files Crofelemer NDA As Napo Seeks To Terminate Their Collaboration

Salix submitted an NDA for HIV-associated diarrhea; it has exclusive rights to market the drug for that indication under a collaboration agreement with Napo but Napo claims Salix has breached the deal by delaying development and commercialization.

BioPharmaceutical Deals

Antibiotics: Start-Ups Ply Novel Targets and Technologies

Microbial drug resistance is a real and growing problem, but drugmakers face disincentives: a plethora of products already on the market, the difficulty of differentiating drugs, and the habit of reserving truly new drugs for emergencies. Big Pharmas are backing out, creating opportunities for small companies who feel they can play successfully. But lack of interest from large partners means biotechs can't access the assets those firms hold, so many start-ups are pairing up with peers. Some firms are building businesses around an abundance of targets derived through genomics. But others are deliberately avoiding working with novel genetic code and instead studying whole cells and physiological changes in organisms. Many firms are addressing the lack of chemical diversity against targets. Some of these are pursuing diversity through natural products like marine microbes, insisting they'll fare better than earlier firms did, in part because of technological advances. Others are trying to create diversity synthetically, by taking structural approaches to understanding targets new and old, as well as compounds. Crystallography, in silico libraries, computational models and mass spectroscopy are key tools in iterative development processes that remain unproven in the anti-infectives field. Some firms are seeking to minimize the risks of novelty, by putting their efforts into developing new versions of antibiotics that worked well before resistance grew. No matter what technological approach start-ups take to developing antibiotics, all face similar challenges external to themselves-primarily in regulatory affairs and funding, but also in hunting Big Pharma partnerships.
BioPharmaceutical Strategy

Natural Products: Providing Diversity or Drug Candidates?

There is tremendous value to be had in exploiting the pharmaceutical uses of natural products, but few companies built around natural-product platforms have enjoyed much success. To succeed, these companies shouldn't be focused on merely providing chemical diversity to the drug industry. Instead, they need to articulate how their libraries will allow them to close in, quickly and with a relatively low risk of failure, on specific drugs for specific diseases.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Shaman Pharmaceuticals Inc.
  • Senior Management
  • Lisa Conte, Pres., CEO, & CFO
    Gerald Reaven, MD, SVP, Research
  • Contact Info
  • Shaman Pharmaceuticals Inc.
    Phone: (415) 952-7070
    213 East Grand Ave.
    S. San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register